Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Has Eyes On EU Rituximab Market Following EC Approval

Ruxience Approved For All Indications Of Reference Brand

Executive Summary

Pfizer has received European Commission approval for the firm’s Ruxience biosimilar to Roche’s MabThera brand, including as a treatment for rheumatoid arthritis, opening the door to a three-way biosimilar fight in the European Union.

You may also be interested in...



Pfizer Biosimilars Sales Hit $1.5bn In 2020 As US Revenues Double

Pfizer’s US biosimilars sales approached $1bn last year, following a number of launches and continued uptake for key products, while revenues in international markets, especially Europe, also increased.

Pfizer Pays Out On Rituximab Biosimilar

Agreements signed between Wyeth and Trubion Pharmaceuticals more than a decade ago have led to Pfizer making royalty payments on its rituximab biosimilar, Ruxience, to Aptevo Therapeutics.

Mylan Partner Mabion Withdraws Rituximab In EU

Mabion’s European applications for biosimilar rituximab have been withdrawn, shortly after partner Mylan indicated it was hopeful of potential market entry this year, with a change of strategy necessitating a new application be filed with the EMA.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149779

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel